Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers

Cancers
Estela Noguera-OrtegaEsther Julián

Abstract

The arsenal against different types of cancers has increased impressively in the last decade. The detailed knowledge of the tumor microenvironment enables it to be manipulated in order to help the immune system fight against tumor cells by using specific checkpoint inhibitors, cell-based treatments, targeted antibodies, and immune stimulants. In fact, it is widely known that the first immunotherapeutic tools as immune stimulants for cancer treatment were bacteria and still are; specifically, the use of Mycobacterium bovis bacillus Calmette-Guérin (BCG) continues to be the treatment of choice for preventing cancer recurrence and progression in non-invasive bladder cancer. BCG and also other mycobacteria or their components are currently under study for the immunotherapeutic treatment of different malignancies. This review focuses on the preclinical and clinical assays using mycobacteria to treat non-urological cancers, providing a wide knowledge of the beneficial applications of these microorganisms to manipulate the tumor microenvironment aiming at tumor clearance.

References

Mar 2, 1988·Journal of the National Cancer Institute·N WolmarkW Lawrence
Apr 5, 1969·Lancet·G MathéF De Vassal
Nov 1, 1995·The Biochemical Journal·R WangM J Groves
Oct 1, 1994·Immunobiology·J L Stanford, C A Stanford
Dec 1, 1994·Foot & Ankle International·P V Spiegl, C M Feiner
Nov 1, 1994·The Journal of Pharmacy and Pharmacology·Y LouM E Klegerman
Mar 21, 1998·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·E Paul, P Devarajan
Oct 3, 1998·Journal of Photochemistry and Photobiology. B, Biology·M Korbelik, I Cecic
Mar 20, 2002·Clinical Oncology : a Journal of the Royal College of Radiologists·L AssersohnI E Smith
May 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M E R O'BrienUNKNOWN SR-ON-12 Study Group
Jun 4, 2004·Cancer Immunology, Immunotherapy : CII·Hiroko NakajimaHaruo Sugiyama
Jul 13, 2004·Current Opinion in Immunology·Graham R Stewart, Douglas B Young
Dec 24, 2004·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Tadeusz PopielaMarek Zembala
Jan 11, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·C L Harper-WynneM E R O'Brien
Oct 22, 2005·Infection and Immunity·Khaleda Rahman QaziCarmen Fernández
Apr 19, 2006·European Journal of Immunology·Dapeng LiLiying Wang

❮ Previous
Next ❯

Citations

Jun 1, 2021·Frontiers in Oncology·Liese VandeborneGauthier Bouche

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01559818
NCT01559819
NCT01308762
NCT03009058
NCT01539824

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.